Monitoring HIV disease with new and clinically useful surrogate markers.
OBJECTIVE
This review aims to identify which patient based observations could enable the development of new surrogate markers for widespread clinical use.


RESULTS
Anti-retroviral drug therapy reduces but does not abolish HIV transmission and replication in all body compartments. It is now clear that monitoring plasma HIV RNA does not help to predict drug failure or to define the existence of persistent viral reservoirs.


CONCLUSIONS
New surrogate markers are required for long-term patient monitoring and to enable the evaluation of additional therapeutic strategies.
Shaunak
Sunil
S
Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK. s.shaunak@imperial.ac.uk
Teo
Ian
I
D015415:Biomarkers; D004279:DNA, Viral / Q000032:analysis; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000175:diagnosis* / Q000188:drug therapy; D016325:HIV Long Terminal Repeat; D006801:Humans; D012333:RNA, Messenger / Q000032:analysis; D014779:Virus Replication
D015415:Biomarkers; D004279:DNA, Viral; D012333:RNA, Messenger